Clinical Trial Update: Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

A National Cancer Institute-sponsored Phase 2 trial of romidepsin (depsipeptide) for recurrent ovarian epithelial cancer and primary peritoneal cancer has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Romidepsin (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: TERMINATED